Zoetis completes acquisition of Nexvet BiopharmaAugust 8, 2017Zoetis Inc., manufacturer of veterinary vaccines and medicines for veterinarians, livestock producers, farmers, and pet owners, announced the completion of its $85 million acquisition of Nexvet Biopharma, a Tullamore, Ireland-based company that manufactures monoclonal antibodies (mAb) for companion animal pain management.
SPONSORED CONTENT1 dose, once a month.Defends dogs against ticks and fleas and also protects against heartworm disease, roundworms, hookworms and tapeworms. + Learn More